Vidutolimod
- Generic Name
- Vidutolimod
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 147063-80-7
- Unique Ingredient Identifier
- D68OW5RS98
- Background
Vidutolimod is a Toll-like receptor 9 (TLR9) agonist. It is an investigational cancer vaccine.
- Associated Conditions
- -
- Associated Therapies
- -
Compassionate Use of Vidutolimod
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT06063746
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 77
- Registration Number
- NCT04916002
- Locations
- 🇺🇸
University of California, Los Angeles, California, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath